Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 1/20 | 0.58 |
| ▸ | ERN1 | O75460 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12334129 | 0.93 | ALDH1A1 (0.67) | CYP2C19CYP2C9POLBCYP2D6SMN1; SMN2 | |
| SCHEMBL12334148 | 0.89 | NPSR1 (0.58) | CYP2C19CYP2C9POLBCYP1A2CYP2D6 | |
| SCHEMBL5103023 | 0.88 | CYP2C19 (0.66) | CYP2C19CYP2C9POLBEPHX2CYP1A2 | |
| SCHEMBL13675357 | 0.88 | PARP1 (0.58) | CYP2C9CYP1A2CYP2D6HPGDPARP1 | |
| SCHEMBL23471125 | 0.87 | CYP2C19 (0.65) | CYP2C19CYP2C9POLBEPHX2CYP1A2 | |
| SCHEMBL279958 | 0.85 | CYP2C19 (0.72) | CYP2C19CYP2C9POLBEPHX2CYP1A2 | |
| SCHEMBL8404677 | 0.85 | CD274 (0.71) | POLBEPHX2CD274HPGDALDH1A1 | |
| SCHEMBL19634805 | 0.84 | CYP2C19 (0.62) | CYP2C19CYP2C9POLBEPHX2CYP1A2 | |
| SCHEMBL9312796 | 0.84 | CYP2C19 (0.70) | CYP2C19CYP2C9POLBEPHX2CYP1A2 | |
| SCHEMBL9312802 | 0.84 | CYP2C19 (0.71) | CYP2C19CYP2C9POLBEPHX2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022128851-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-23 | — | — | WO | disclosed |
| US-8207186-B2 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090197908-A1 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | MERCK SHARP & DOHME LLC | 2009-08-06 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7550478-B2 | Tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197908-A1 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | MET, RET, ERBB2 | CYP2C19 2411/4885CYP2C9 2496/4885POLB 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.